跳到主要內容

簡易檢索 / 詳目顯示

回結果列表
研究生： 何淑珊
Sampath, Shubha
論文名稱： 歐洲主要市場奈米科技產品之商業化
Nano technology product commercialization in key european markets
指導教授： 何小台
Ho, Chester
學位類別： 碩士
Master
系所名稱： 商學院 - 國際經營管理英語碩士學位學程(IMBA)
International MBA Program College of Commerce(IMBA)
論文出版年： 2009
畢業學年度： 97
語文別： 英文
論文頁數： 124
中文關鍵詞： 奈米科技
相關次數： 點閱：93  下載：80 
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報

    • 歐洲主要市場奈米科技產品之商業化

    Objectives of the research: To identify commercial possibilities and develop an entry strategy for Nano technology product in the healthcare segment for key Western European markets. To investigate the Benelux and German customer landscape by collecting data via hospital and field expert interviews. To compile the research findings to formulate the Europe market entry strategy and provide future recommendations.

    Executive Summary
    This paper sets out to research the European market entry possibilities of ‘Nano technology Product’, an antimicrobial surface treatment that uses nano-scale technology to kill bacteria and viruses upon contact.

    Through face-to-face interviews with infectious disease professionals in the hospital environment, a research was conducted to understand, what needs end-users have and which procedures and products are currently employed. Furthermore, the research aimed to reveal how aware potential customers are about nanotechnology in general and ‘Nano technology Product’ in specific, what institutions govern the landscape and how end users’ budgets are set.

    Based on an analysis of the institutional landscape in the Netherlands, Germany and Belgium, a recommended market entry strategy is created for the ‘Nano technology Product’.

    Over View 2
    Executive Summary 2
    Chapter 1: Introduction 7
    1.1 The Company 7
    1.2 ‘Nano technology Product’ 7
    Chapter 2: Key Issues 8
    2.1 Identified Issue 8
    2.2 Overall Objective 8
    2.3 Research Question 8
    Chapter 2: Key Issues 9
    3.1 Conceptual Framework 9
    3.2 Procedure 9
    3.2.1 Background Research 9
    3.2.2 Hospital and Field Expert Selection 9
    3.2.3 Interviews 10
    Chapter 4: Main Issues 11
    4.1 Infectious Diseases 11
    4.1.1 Overview 11
    4.1.2 The Netherlands 11
    4.1.3 Germany 12
    4.1.4 Belgium 12
    4.2 Transmission Mechanisms 13
    4.2.1 Overview 13
    4.2.2 Hand Hygiene & Compliance 13
    4.2.3 Surfaces 13
    4.2.4 Linens 13
    4.2.5 Air Travel 13
    Chapter 5: Product Fit 16
    5.1 Product Perception 16
    5.1.1 Overview 16
    5.1.2 Awareness 16
    5.1.3 Concerns 17
    5.1.4 Interest 17
    5.2 Applications 17
    5.2.1 Overview 17
    5.2.2 Application Areas 18
    5.2.3 Specific Applications 18
    Chapter 6: Procedural & Competitive Landscape 20
    6.1 Hospital Hygiene Products & Procedures 20
    6.1.1 Overview 20
    6.1.2 Hand and Surface Disinfection 21
    6.1.3 Disinfection of Linens 22
    6.1.4 Air Filtration 22
    6.1.5 Water Filtration 23
    6.2 Hospital Hygiene Practices 24
    6.3 Competing Technologies & New Product Research 25
    6.3.1 Overview 25
    6.3.2 The Netherlands 25
    6.3.3 Germany 25
    6.3.4 Belgium 25
    Chapter 7: Fiscal & Institutional Landscape 27
    7.1 Relevant Institutions 27
    7.1.1 Overview 27
    Table 7.1: Institutional landscape overview 27
    7.1.2 The Netherlands 28
    7.1.3 Germany 30
    7.1.4 Belgium 32
    7.1.5 Europe 34
    7.2 Key Decision Makers 34
    7.2.1 Overview 34
    7.2.2 Key Decision Makers 35
    7.3 Outbreak Procedures 35
    7.3.1 Overview 35
    7.3.2 The Netherlands 36
    7.3.3 Germany 37
    7.3.4 Belgium 38
    7.4 Budget 39
    7.4.1 Overview 39
    7.4.2 The Netherlands 39
    7.4.3 Germany 39
    7.4.4 Belgium 40
    Chapter 8: Conclusions 40
    8.1 Main Issues 40
    8.2 Product Fit 42
    8.3 Procedural & Competitive Landscape 43
    8.4 Institutional Landscape 44
    Chapter 9: Recommendations 49
    9.1 Market Entry Point 49
    9.1.1 Germany 49
    9.1.2 Belgium 50
    9.1.3 The Netherlands 50
    9.2 Market Entry Strategy 51
    9.2.1 Germany 51
    9.2.2 Belgium 53
    9.2*Ireland as the Port of Entry
    9.3 Further Research 54
    9.3.1 Methodology Insights 54
    9.3.2 Further Research Opportunities 54
    Chapter 10: Reflections 55
    10.1 Learnings & Limitations 55
    10.1.1 Anticipated Challenges 55
    10.1.2 Actual Challenges 55
    10.2 Value Created 56
    Bibliography 57
    Appendices 59
    Appendix A: Sample Interview Questionnaire 59
    Appendix B: Sample Online Survey 62
    Appendix C: Interview Contact List 66
    Appendix D:Main Issues 67
    Appendix E: Ten-step outbreak scheme by Robert Koch Institute 68
    Appendix F: Interview Transcripts 70
    Appendix G: Berlin ESCAIDE Conference Notes 120
    Appendix H: Online Survey Results 124

    Articles & Reports
     Karchmer, Durbiny, Simontony, & Farry (2002), Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus, Journal of Hospital Infection
     IGZ (Inspectie voor de Gezonsheidszorg, or Healthcare Inpection) (2008), Rapport van het onderzoek naar het peroperatief proces in de IJsselmeerziekenhuizen te Lelystad en Emmeloord op 5 en 12 september 2008, available on www.igz.nl
     Kim, Oh & Simor (2001), The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals, Infection Control & Hospital Epidemiology
     Kunori, T. (2001), Cost-effectiveness of different MRSA screening methods, Journal of Hospital Infection
     Wertheim, H.F.L. et al. (2004), Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic, Journal of Hospital Infection
     Stone, K. (2008), The Rise of MRSA in Pigs and the Health Risk to Humans, http://www.naturalnews.com/023725.html
    Websites
     http://www.cbo.nl/english/article20030512115620/articleCBOextra_view, Accessed November, 11 2008
     http://www.allesovermrsa.nl/, Accessed on December, 10 2008
     www.cdc.com, Accessed on December, 12 2008
     https://www.cia.gov/library/publications/the-world-factbook/, Accessed on December, 13 2008
     https://portal.health.fgov.be/portal/page?_pageid=56,4190386&_ dad=portal&_schema=PORTAL&_menu=menu_3_1, Accessed on November, 11 2008
     http://www.iph.fgov.be/Index.asp?Lang=EN&Proc=MISSION, Accessed on November, 31 2008
     http://www.rivm.nl/en/aboutrivm/what/, Accessed on November, 11 2008
     http://www.vah-online.de/cmsmadesimple/index.php?page=vah-2, Accessed on November, 11 2008
     http://www.infectieziekten.org/, Accessed on December, 11 2008
     http://www.wip.nl/UK/, Accessed on December, 11 2008
     http://www.vah-online.de/cmsmadesimple/uploads/PDF/FlyerVAH_116.pdf, Accessed on December, 5 2008
     http://www.ilpi.com/msdS/ref/concentration.html, Accessed on December, 12 2008
     http://www.rki.de/cln_100/nn_201414/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Ausbr__Rili,templateId=raw,property=publicationFile.pdf/Ausbr_Rili.pdf, Accessed on December, 12 2008

    Articles & reports
    • Amnesty International (2008), Voorwoord jaarboek 2008: Geschonden beloften. http://www.amnesty.nl/bibliotheek_vervolg/jaarboek2008_voorwoord
    • Cernic, J.L. (2008), Corporate Responsibility for Human Rights: A Critical Analysis of the OECD Guidelines for Multinational Enterprises, Hanse Law Review.
    • Books
    • Sachs, Jeffrey D. (2008) Common Wealth: economics for a crowded planet, Londen: Penguin Books Ltd.

    QR CODE
    :::